| While our annual list of the top 20 pharmas by revenue may seem familiar, months of M&A, rejigs, reorgs, selloffs and cost cuts have left no company looking as they did the year before. Vaccines played a large role, with the leading developers all claiming spots in the top 10. Today, many on our list are racing to find treatments for COVID-19. But an effective shot could still be years away, according to one analysis—meanwhile, the leader of the U.S. agency quarterbacking vaccine research has stepped down, calling for investigations into those “placing politics and cronyism ahead of science.” | |
|
Featured Story | | | Thursday, April 23, 2020 Ex-BARDA chief Rick Bright has launched an astonishing attack against “politics and cronyism” days after being kicked out of the agency leading the government’s push for a COVID-19 vaccine. |
|
|---|
|
|  | May 5, 2020 | 1pm ET / 10am PT Learn how Signatera, a breakthrough technology, can be applied in early stage and late stage cancer trials, potentially enriching for patients most likely to respond to therapy, accelerating time to trial readout, or identifying early relapsers. Register Now! |
Top Stories Of The Week The top players in pharma know how to adapt. After M&A, selloffs, cost cuts and therapeutic rejigs, the companies on this list may largely wear the same names, but none look exactly as they did for last year's edition. Friday, April 17, 2020 Could a COVID-19 vaccine really be ready in 12 to 18 months? Global analytics firm Clarivate applied machine learning to leading vaccine candidates from Moderna and Inovio and made some sobering forecasts about both the FDA approval timeline and the probability of success. Wednesday, April 22, 2020 The current state of antibody testing for COVID-19 is “a disaster,” said Roche CEO Severin Schwan, as a large number of potentially inaccurate tests enter the market fueled by sky-high demand. Friday, April 17, 2020 Early in the U.S. COVID-19 outbreak, Biogen’s February meeting in Boston played a central role in spreading the virus in Massachusetts and beyond. Now that many employees have recovered, they’re donating blood samples to a “biobank" to help researchers learn more about the virus. Thursday, April 16, 2020 The world is watching and waiting for data to see whether Gilead's investigational antiviral remdesivir can help fight COVID-19. And while some leaked early results suggest that it can, industry watchers will need to wait for data from Gilead's own controlled phase 3 study to know for sure. Monday, April 20, 2020 Is Gilead's remdesivir the COVID-19 panacea everyone is hoping for, and should four experimental drugs that were studied years ago in autoimmune disease and cancer now also be tested for their ability to halt the virus's replication and spread? Two newly released studies aim to help answer those questions. Monday, April 20, 2020 Last Thursday, analysts urged caution when reading into leaked data for Gilead’s COVID-19 hopeful remdesivir, stressing that the numbers came from a single site participating in a study with no control group. Now, a congressman is asking the Securities and Exchange Commission to investigate. Friday, April 17, 2020 Biopharma companies all vow to help patients, but how do they fare in creating a healthy workplace environment for their employees? Roche’s Genentech, Novo Nordisk and AbbVie ranked as the top 3 on Fortune’s U.S. best workplaces in biopharma in 2020, a list that’s heavily based on employee survey. Friday, April 17, 2020 Two remdesivir trials in China have been suspended due to low enrollment. The FDA has cleared a trio of Indian Pharmas' production sites this month. CanSino's recombinant shot became the first COVID-19 vaccine to enter phase 2 trial. And more. Friday, April 17, 2020 Drugmakers are rushing to supply millions of doses of chloroquine phosphate, a cheap generic in testing as a possible treatment for COVID-19, after public interest sent demand through the roof. But donated batches of the drug from Bayer, which haven't been approved by the FDA, are drawing quality concerns. Tuesday, April 21, 2020 Consumers' impression of pharma companies has soared during the COVID-19 pandemic, with 40% now reporting that they have a more positive view of the industry than they did before the pandemic began, according to recent data from The Harris Poll. Resources Sponsored by: Blue Latitude Health Report: Think you’re patient-centric? Think again. Find out how patients really feel about patient-centricity. Learn what they would like to experience along with tools and tips for maximising patient engagement across the product life cycle¬ – from clinical trials to service design and creative campaigns. Sponsored by: BBK Worldwide Leverage strategic solutions to respond to immediate challenges to patient and site engagement from COVID-19, and learn to maximize the FDA guidance on the conduct of clinical trials during a pandemic. Sponsored by: Oracle Health Sciences The research conducted here is to help understand and solve the top challenges in clinical operations, to remove barriers that are slowing down our ability to bring new drugs to market as quickly as possible to patients waiting in need. Sponsored by: Clinical Ink This white paper includes a Phase III case study and discusses BYOD advantages and misconceptions, regulatory, copyright, and equivalency considerations. Sponsored by: Research Solutions Turn your drug failures into competitive advantage. Sponsored by: ICON How will US payers evaluate and manage digital therapeutics? Get insights and recommendations on successful market access considerations. Sponsored by: Copyright Clearance Center Despite advances in content aggregation and search, silos still limit the free flow of data and analytics. So, what can be done, and how can you get more value from the data you already have? Sponsored by: Altran This whitepaper highlights the challenges of implementing the right digital twin strategy while providing key use cases in the manufacturing domain for which a digital twin is extremely useful and several examples of technology trends that will shape the future. Sponsored by: Patheon, by Thermo Fisher Scientific Poorly soluble molecules hindering your workflow? Sponsored by: eClinical Solutions Key findings from the 2019 Life Sciences Data & Analytics Survey conducted by the Tufts Center for the Study of Drug Development will be unveiled during this live webinar led by industry expert and study lead, Ken Getz, Director of Sponsored Programs and Associate Professor. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Catalent This whitepaper discusses the benefits of end-to-end solutions and share case studies on how flexible manufacturing strategies can accommodate the changing landscape of pharmaceutical products and help bring a drug to market. Sponsored by: Clarify Health Pharma launch teams spend significant resources on data and analytics with limited ROI. Read this case study to learn how a Life Sciences company identified two times more patients best suited for therapy, using Clarify’s deep and longitudinal patient and HCP insights. | 
